- To take the test online, go to our secure Web site at www.nursingcenter.com/ce/ajn.
- To use the form provided in this issue, record your answers in the test answer section of the CE enrollment form below. Each question has only one correct answer. You may make copies of the form.
- Complete the registration information and course evaluation. Mail the completed enrollment form and registration fee of $56.95 to: Lippincott Williams and Wilkins, CE Group, 2710 Yorktowne Blvd., Brick, NJ 08723. You will receive your certificate in four to six weeks. For faster service, include a fax number and we will fax your certificate within two business days of receiving your enrollment form. You will receive your CE certificate of earned contact hours and an answer key to review your results. There is no minimum passing grade.
- Registration deadline is April 30, 2014.
DISCOUNTS AND CUSTOMER SERVICE
- Send in together two or more tests from any nursing journal published by Lippincott, Williams and Wilkins (LWW), and deduct $0.95 from the price of each test.
- We also offer CE accounts for hospitals and other health care facilities online at www.nursingcenter.com. Call 1-800-787-8985 for details.
LWW, publisher of AJN, will award 8 contact hours for this continuing nursing education activity.
LWW is accredited as a provider of continuing nursing education by the Commission on Accreditation of the American Nurses Credentialing Center (ANCC).
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 8 contact hours. LWW is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454. Your certificate is valid in all states.
The ANCC's accreditation status of the LWW Department of Continuing Education refers to its continuing nursing educational activities only and does not imply Commission on Accreditation approval or endorsement of any commercial product.
CE TEST QUESTIONS
To provide registered professional nurses with an understanding of the state of the science in the prevention and management of osteoarthritis (OA).
After reading these articles and taking this test, you should be able to
- discuss the epidemiology and barriers to early assessment and treatment of OA.
- compare and contrast various treatment options for persons with OA.
- Which statement is true regarding osteoarthritis (OA) in the United States?
- It's the most common cause of disability.
- Male gender is a primary risk factor.
- It's the second most common form of arthritis.
- Pain is greater in men than in women.
- The top barrier to improving early assessment and treatment of OA is that
- OA treatment generally is not considered a priority because comorbid conditions are of higher priority.
- there are too few evidence-based assessment tools for monitoring OA progression.
- there's a lack of coordinated, integrated, multidisciplinary care planning and delivery.
- primary health care providers lack knowledge and have inaccurate or inappropriate beliefs about OA.
- The number one practice barrier to implementing the best OA practices is
- a lack of knowledge among nurse faculty and clinicians about best practices for OA.
- that late presentation at the time of diagnosis results in treatment initiation after significant disease progression.
- a lack of financing for nursing interventions and nurse-managed care.
- that health care access is limited because of patients’ inadequate financial resources or a lack of providers.
- Compared with whites, which ethnic group reports more severe joint pain from arthritis?
- non-Hispanic blacks
- persons from the Middle East
- Eastern Europeans
- What can bring on early-onset OA within 10 years?
- a diet high in acidic foods
- a major joint injury
- a 5-lb. weight gain
- The lifetime risk (by age 85) of symptomatic knee OA is nearly
- 1 in 2.
- 1 in 3.
- 1 in 4.
- 1 in 5.
- The 3 strongest modifiable risk factors for symptomatic knee OA include all of the following except
- occupations involving excessive mechanical stress.
- The most significant contributor to the primary form of OA is
- The American College of Rheumatology recommends which medication as a primary agent for OA?
- glucosamine sulfate
- In a study by Katz and Lee (2007), most users of complementary and alternative medicine (CAM) used
- mind–body therapies.
- herbs and supplements.
- body-based methods.
- dietary practices.
- There's a moderate level of evidence supporting the use of what therapy to manage pain in persons with knee OA?
- Therapeutic Touch
- t'ai chi ch'uan
- Healing Touch
- Significant improvement in functioning in persons with knee OA has been seen with the use of
- pycnogenol (pine bark extract).
- glucosamine sulfate.
- chondroitin sulfate.
- Eating fruits and vegetables for weight control is an example of
- self-management education.
- ongoing supportive follow-up.
- environmental changes.
- supportive provider interactions.
- Interventions are more effective when they include at least how many sessions of supervised contact?
- Which statement is true regarding acetaminophen?
- Acetaminophen toxicity is the second most common cause of acute liver failure in the United States.
- It's recommended for the treatment of moderate-to-severe OA pain.
- Unintentional overdose is the leading cause of acetaminophen-induced hepatotoxicity.
- It's more effective in improving function in OA patients than nonsteroidal antiinflammatory drugs (NSAIDs).
- NSAID users face an increased risk of
- fracture compared with opioid users.
- congestive heart failure.
- chronic obstructive pulmonary disease.
- Rehabilitation interventions for knee or hip OA from the Centers for Disease Control and Prevention include
- 75 minutes of moderate-intensity aerobic activity per week.
- 150 minutes of vigorous-intensity aerobic activity per week.
- balance work 3 days per week, if at risk for falling.
- strengthening exercises at least once per week.
- The authors of a 2008 Cochrane review noted that the benefits gained from exercise by persons with knee OA were comparable to benefits from
- disease-modifying drugs.
- electrical stimulation.